Abstract 4418
Background
High field iMRI with integrated neuronavigation system is an advanced diagnostic tool gives information about extent of resection allowing immediate update of neuronavigation parameters after anatomic changes occuring as a result of tumour resection, cerebrospinal fluid evacuation and brain shift.
Methods
20 CNS tumour cases underwent Brain suite MRI prior to surgery, then surgery was done after patient registration in navigation system using iMRI. Preoperative tumor volume was manually segmented, compared with intraoperative volume after first resection attempt and final post operative volume after surgical closure to calculate extent of resection (EOR).Descriptive statistics were used to find mean, SD, frequency, percentage of variables. Normally distributed interval data reported as means by two-sample t- test. Non-normally distributed interval/ordinal data reported as median{inter-quartile ranges} and compared among groups by Wilcoxon exact test to obtain EOR values.
Results
20 cases allocated to two groups (G), 1st in whom surgery was complete after first iMRI and 2nd who underwent further tumour removal. In G1 surgery was terminated in 11 cases after iMRI, GTR in 81.8% cases. iMRI showed subtotal resection(STR) in 18.2% patients but surgery stopped owing to infiltration of eloquent brain. Median preoperative tumour volume was 40.8cm3. Median postoperative tumour volume was 0.81cm3 with a significant p value (<0.001). Median EOR was 98.5% in G1. In G2, 9 of 20 (45%) underwent further resection of residual tumour after post resection iMRI. GTR in 77.7% and STR in 22.3%, because of tumour’s close proximity to eloquent brain area. Median % of tumour resection after the first iMRI was 82.65%. Median EOR from the final postoperative iMRI was 98.3%. GTR increased from 45% to 80 % after use of iMRI. Median % of residual tumour volume significantly decreased from 5.3% to 1.7 % (p value <0.001). Mean control tumour volume was 9.67% and final post operative volume of 4.72% , which is almost half of intraoperative tumour volume (p value <0.001).
Conclusions
iMRI has potential role in maximizing gross total resection rates of CNS tumours which has an overall great prognostic impact.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional ethics committee, Max Superspeciality Hospital, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract